The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDA) is characterized by its highly immunosuppressive tumor microenvironment (TME) that limits T cell infiltration and induces T cell hypofunction. Mesothelin-redirected chimeric antigen receptor T cell (meso-CAR T cell) therapy has shown some efficacy in clinical trials but antitumor efficacy remains modest. We hypothesized that combined meso-CAR T cells with an oncolytic adenovirus expressing TNF-α and IL-2 (Ad5/3-E2F-D24-TNFa-IRES-IL2, or OAd-TNFa-IL2) would improve efficacy. OAd-TNFa-IL2 enhanced the antitumor efficacy of meso-CAR T cells in human-PDA-xenograft immunodeficient mice and efficacy was associated with robustly increased tumor-infiltrating lymphocytes (TILs), enhanced and prolonged T cell function. Mice treated with parental OAd combined with meso-CAR T developed tumor metastasis to the lungs even if primary tumors were controlled. However, no mice treated with combined OAd-TNFa-IL2 and meso-CAR T died of tumor metastasis. We also evaluated this approach in a syngeneic mouse tumor model by combining adenovirus expressing murine TNF-α and IL-2 (Ad-mTNFa-mIL2) and mouse CAR T cells. This approach induced significant tumor regression in mice engrafted with highly aggressive and immunosuppressive PDA tumors. Ad-mTNFa-mIL2 increased both CAR T cell and host T cell infiltration to the tumor and altered host tumor immune status with M1 polarization of macrophages and increased dendritic cell maturation. These findings indicate that combining cytokine-armed oncolytic adenovirus to enhance the efficacy of CAR T cell therapy is a promising approach to overcome the immunosuppressive TME for the treatment of PDA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationTalimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Ryan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
O’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,803
Self-citationKochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Liyanage, U. K., Moore, T. T., Joo, H.-G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J. A., Strasberg, S. M., Eberlein, T. J., Goedegebuure, P. S., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.5.2756 · Cited by 1,467
Humanized mice in translational biomedical research
Shultz, L. D., Ishikawa, F., & Greiner, D. L. (2007) · Nature Reviews Immunology · doi:10.1038/nri2017 · Cited by 1,279
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191
Humanized mice in translational biomedical research
Shultz, L. (2007) · The Mouseion at the JAXlibrary (Jackson Laboratory) · Cited by 1,036
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Self-citationLocke, F. L., Neelapu, S. S., Bartlett, N. L., Siddiqi, T., Chavez, J. C., Hosing, C. M., Ghobadi, A., Budde, L. E., Bot, A., Rossi, J. M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.020 · Cited by 620
Going viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Antibody phage display technology and its applications
Hoogenboom, H. R., de Bruı̈ne, A. P., Hufton, S. E., Hoet, R. M., Arends, J.-W., & Roovers, R. C. (1998) · Immunotechnology · doi:10.1016/s1380-2933(98)00007-4 · Cited by 512
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Morello, A., Sadelain, M., & Adusumilli, P. S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0583 · Cited by 477
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14
Wang, H., Li, Z.-Y., Liu, Y., Persson, J., Beyer, I., Möller, T., Koyuncu, D., Drescher, M. R., Strauss, R., Zhang, X.-B., et al. (2011) · Nature Medicine · doi:10.1038/nm.2270 · Cited by 432
Self-citationMoon, E. K., Wang, L.-C., Dolfi, D. V., Wilson, C. B., Ranganathan, R., Sun, J., Kapoor, V., Scholler, J., Puré, E., Milone, M. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2627 · Cited by 404
Self-citationMesothelin targeted cancer immunotherapy
Hassan, R., & Ho, M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.028 · Cited by 340
Nishio, N., Diaconu, I., Liu, H., Cerullo, V., Caruana, I., Hoyos, V., Bouchier-Hayes, L., Savoldo, B., & Dotti, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0697 · Cited by 331
Chimeric antigen receptor T-cell therapy for solid tumors
Newick, K., Moon, E., & Albelda, S. M. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.6 · Cited by 236
Brown, M. C., Holl, E. K., Boczkowski, D., Dobrikova, E., Mosaheb, M., Chandramohan, V., Bigner, D. D., Gromeier, M., & Nair, S. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4220 · Cited by 224
Tanoue, K., Rosewell Shaw, A., Watanabe, N., Porter, C., Rana, B., Gottschalk, S., Brenner, M., & Suzuki, M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1577 · Cited by 219
Rosewell Shaw, A., Porter, C. E., Watanabe, N., Tanoue, K., Sikora, A., Gottschalk, S., Brenner, M. K., & Suzuki, M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.010 · Cited by 219
Stromnes, I. M., Schmitt, T. M., Hulbert, A., Brockenbrough, J. S., Nguyen, H. N., Cuevas, C., Dotson, A. M., Tan, X., Hotes, J. L., Greenberg, P. D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.022 · Cited by 200
Ranki, T., Pesonen, S., Hemminki, A., Partanen, K., Kairemo, K., Alanko, T., Lundin, J., Linder, N., Turkki, R., Ristimäki, A., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0121-5 · Cited by 199
Self-citationZeng, D.-Q., Yu, Y.-F., Ou, Q.-Y., Li, X.-Y., Zhong, R.-Z., Xie, C.-M., & Hu, Q.-G. (2016) · Oncotarget · doi:10.18632/oncotarget.7282 · Cited by 192
The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer
Li, J., Wang, J., Chen, R., Bai, Y., & Lu, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14919 · Cited by 179
Kho, D., MacDonald, C., Johnson, R., Unsworth, C., O'Carroll, S., Mez, E., Angel, C., & Graham, E. (2015) · Biosensors · doi:10.3390/bios5020199 · Cited by 178
Prognostic Significance of Tumor-Infiltrating Lymphocytes for Patients With Colorectal Cancer
Lee, J. H. (2012) · Archives of Surgery · doi:10.1001/archsurg.2012.35 · Cited by 176
Kanerva, A., Zinn, K. R., Chaudhuri, T. R., Lam, J. T., Suzuki, K., Uil, T. G., Hakkarainen, T., Bauerschmitz, G. J., Wang, M., Liu, B., et al. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00200-4 · Cited by 171
Self-citationBeatty, G. L., & O’Hara, M. H. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.010 · Cited by 139
Havunen, R., Siurala, M., Sorsa, S., Grönberg-Vähä-Koskela, S. A. M., Behr, M., Tähtinen, S., Santos, J. M., Karell, P., Rusanen, J., Nettelbeck, D. M., et al. (2017) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2016.12.004 · Cited by 136
Self-citationBarrett, D. M., Liu, X., Jiang, S., June, C. H., Grupp, S. A., & Zhao, Y. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.075 · Cited by 117
Self-citationTNFα induces expression of the chemoattractant cytokine RANTES in cultured mouse mesangial cells
Wolf, G., Aberle, S. W., Thaiss, F., Nelson, P. J., Krensky, A. M., Neilson, E. G., & Stahl, R. A. K. (1993) · Kidney International · doi:10.1038/ki.1993.314 · Cited by 91
Kim, K. H., Dmitriev, I. P., Saddekni, S., Kashentseva, E. A., Harris, R. D., Aurigemma, R. E., Bae, S., Singh, K. P., Siegal, G. P., Curiel, D. T., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.06.003 · Cited by 91
Immune cell infiltration of primary and metastatic lesions: Mechanisms and clinical impact
Talmadge, J. E. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.12.002 · Cited by 83
James, F., Jiminez-Linan, M., Alsop, J., Mack, M. L., Song, H., Brenton, J. D., Pharoah, P. D. P., & Ali, H. R. (2017) · BMC Cancer · doi:10.1186/s12885-017-3585-x · Cited by 78
Pancreatic Ductal Adenocarcinoma: A Review of Immunologic Aspects
Wachsmann, M., Pop, L. M., & Vitetta, E. S. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31824a4d79 · Cited by 72
Tähtinen, S., Grönberg-Vähä-Koskela, S. A. M., Lumén, D., Merisalo-Soikkeli, M., Siurala, M., Airaksinen, A. J., Vähä-Koskela, M. J. V., & Hemminki, A. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0220-t · Cited by 72
Self-citationMUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment
Mukherjee, P., Ginardi, A. R., Madsen, C. S., Tinder, T. L., Jacobs, F., Parker, J., Agrawal, B., Longenecker, B. M., & Gendler, S. J. (2001) · Glycoconjugate Journal · doi:10.1023/a:1022260711583 · Cited by 64
Nakasone, Y., Fujimoto, M., Matsushita, T., Hamaguchi, Y., Huu, D. L., Yanaba, M., Sato, S., Takehara, K., & Hasegawa, M. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.09.005 · Cited by 63
Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
Yin, J., Markert, J. M., & Leavenworth, J. W. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00136 · Cited by 57
Siurala, M., Havunen, R., Saha, D., Lumén, D., Airaksinen, A. J., Tähtinen, S., Cervera-Carrascón, V., Bramante, S., Parviainen, S., Vähä-Koskela, M. J. V., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.137 · Cited by 56
Self-citationBeatty, G. L., O’Hara, M. H., Nelson, A. M., McGarvey, M., Torigian, D. A., Lacey, S. F., Melenhorst, J. J., Levine, B. L., Plesa, G., & June, C. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3007 · Cited by 55
Self-citationTähtinen, S., Kaikkonen, S., Merisalo-Soikkeli, M., Grönberg-Vähä-Koskela, S. A. M., Kanerva, A., Parviainen, S., Vähä-Koskela, M. J. V., & Hemminki, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131242 · Cited by 49
Self-citationCharacteristics of chemokine signatures elicited by EGF and TNF in ovarian cancer cells
Son, D., Kabir, S. M., Dong, Y., Lee, E.-S., & Adunyah, S. E. (2013) · Journal of Inflammation · doi:10.1186/1476-9255-10-25 · Cited by 42
Cited by
Metabolic barriers to cancer immunotherapy
DePeaux, K., & Delgoffe, G. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00541-y · Cited by 597
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Albelda, S. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 517
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Immunotherapy for pancreatic cancer: A 2020 update
Schizas, D., Charalampakis, N., Kole, C., Economopoulou, P., Koustas, E., Gkotsis, E., Ziogas, D., Psyrri, A., & Karamouzis, M. V. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102016 · Cited by 458
Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities
Balachandran, V. P., Beatty, G. L., & Dougan, S. K. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.038 · Cited by 444
Metadata
- Authors
- Watanabe, K., Luo, Y., Da, T., Guedan, S., Ruella, M., Scholler, J., Keith, B., Young, R. M., Engels, B., Sorsa, S., Siurala, M., Havunen, R., Tähtinen, S., Hemminki, A., & June, C. H.
- Venue
- JCI Insight
- Published
- 2018-04-05
- Volume
- 3
- Issue
- 7
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W2795515854
- Cited by
- 283
- References
- 49
- FWCI
- 15.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.